Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Parallel-arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment With Brenipatide Compared With Placebo in Adult Participants With Major Depressive Disorder Who Have Partial Response to Antidepressant Therapy (RENEW-MDD-3)
NCT07928245 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Randomized, Double-blind, Parallel-arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment With Brenipatide Compared With Placebo in Adult Participants With Major Depressive Disorder Who Have Partial Response to Antidepressant Therapy (RENEW-MDD-3)
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- July 31, 2028
- Enrollment
- 330 (estimated)
- Sites
- 75
Conditions
As the registry lists them; a condition with its own page is linked.
Arms
As registered; 2 arms.
-
Brenipatide
Brenipatide administered subcutaneously (SC) + standard of care (SoC) anti-depressant
-
Placebo
Placebo administered SC + SoC anti-depressant
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS-9) Score
Lead sponsor's other trials
Eli Lilly and Company, most recent start first.
+2,102 more trials See the organization page
Similar trials
Same condition (Major Depressive Disorder) and phase, most recent start first.
+396 more trials See the condition page